Argentina begins administering second Sputnik V doses

coronavirus
Credit: Pixabay/CC0 Public Domain

Argentina's government began administering second doses of the Russian Sputnik V coronavirus vaccine Tuesday after receiving another shipment of 300,000 shots at the weekend.

Argentina began its immunization campaign on December 29 with the first 300,000 doses of the made by Russia's Gamaleya laboratory.

It is prioritizing in this first phase.

"The has been developing in a timely fashion," Health Minister Gines Gonzalez Garcia said.

The country of 44 million has recorded more than 1.8 million cases and almost 46,000 deaths from COVID-19.

Argentina was the first Latin American country, on December 23, to approve the "emergency use" of Sputnik V despite a lack of clinical trials.

The government has an agreement to purchase another 19.4 million doses by the end of February with an option for an extra five million.

Argentina has committed to buying 51 million doses in total and has also signed deals to purchase the AstraZeneca/Oxford and Covax vaccines.

Negotiations are ongoing to procure the vaccine made by US pharmaceutical giant Pfizer with German biotechnology firm BioNTech.

The next stages of the immunization program will see the over 60s and people suffering from at least two illnesses receiving vaccines.

Meanwhile, Chile began immunizing its on Monday, starting with those over 80 or suffering from .

Chile started immunizing health care workers on December 24 and has signed deals to purchase 30 million doses.

It has reported 670,000 cases and 17,500 deaths amongst its 18 million population.


Explore further

Argentina first in Latin America to approve Russian vaccine

© 2021 AFP

Citation: Argentina begins administering second Sputnik V doses (2021, January 19) retrieved 1 March 2021 from https://medicalxpress.com/news/2021-01-argentina-sputnik-doses.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments